Also in this playlist...
This transcript is automatically generated
Right now the battle to create the next Blockbuster drug to treat hepatitis C which.
Killed some 121000 people every year is opening up on new multiple fronts and companies.
Like a killing in -- on the front lines shares of this company.
Are down nearly percent right now on no news at the moment but they are skyrocketing some 60%.
So far this year.
And more than a 100% over the past 52 weeks on promising news for its key treatment.
And we're gonna talk about that right now in a Fox Business exclusive from Stamford Connecticut with Mary Kay Fenton who is the chief financial officer.
Of a Killian.
Overall Mary K I mean over just three months it's up a 113%.
On the struck that you have.
Well it's -- kind of a boring name but it's it's doing some exciting things tell us what this drug does and how promising it is for people who suffer and sometimes died.
-- you know you're absolutely right Liz this is a very exciting time in the therapeutic area of hepatitis C across health care sectors and.
We think it's for a couple of reasons first the numbers are so daunting with a 170 million people worldwide infected with hepatitis C.
New data from UCLA indicate that five and a half to seven and a half million of those are in the US.
And on those about two thirds don't even realize they're infected so we call -- the silent epidemic and it's actually more prevalent in the US -- HIV.
So it's it's very large market our market.
Metrics indicate that the market's going to be 26 billion by twenty when he -- huge but what what is it that your drug does.
That's different from what's already out there or being developed by other companies.
Our drug is hits all the key attributes of what prescribe person patients are looking for -- they're looking for therapies in contrast to what's currently available.
That have efficacy against broad Gena types they're six different Gena types of hepatitis C.
They're looking for therapies that are orally available most therapies these days include an injectable called interferon which can have some pretty atrocious side effects with of -- its own.
And they're looking for therapies that are convenient and that are durable.
-- -- shape of Mary K because.
So expensive and and they have very expense you've got a competitor called vertex vertex that drug it's 50000 dollars for twelve weeks of therapy can you beat them not only on the efficacy but also on the price.
Who we think we can't we think we absolutely have beaten them on efficacy.
-- -- Revere which is the name of that drug by vertex.
Has some pretty.
Nasty side effects of its own and our drug has been shown in clinical studies to be very benign in terms of side effects.
We just announced data last week it JPMorgan that are dragging a CH 1625 that boring name your reference to -- It actually has a 100% efficacy in patients that took our drug over the course of.
Three different dose groups so.
We're pretty pleased with those results when -- -- hit the market people are sitting here suffering and in some cases on the verge of death they wanted to witness -- -- the market.
Yeah there's a quite a number of therapies that are being developed right now the pace of change in the hepatitis C in clinical development field is rapid.
And the therapies that were referencing here that one of which is the -- combination they're all oral interferon free are about two to three years away.
-- was key people did not wanna check you themselves it's a pain in many ways -- Maalox quick question about the stock -- insider selling lately many executives including yourself have sold shares particularly last week.
On on some that were talked options that happen even expired yet is then is there anything insidious about that that we should be concerned about.
Not at all every single sale that went off last week was attributed 28 pre planned ten B five sales plan that was put in place.
In the early part of 2011 when our stock frankly was in the five and six dollar range so we actually betting on a win with this company eleven now if they're all.
And now and and they're really represented a small fraction of what the management team holds.
Eleven dollars and eighteen cents is where it stands right now ticker symbol ACH and -- Mary Kay Fenton thank you very much for joining us and again that Europe has been granted fast track designation that and so that is that means that it's but it's put on the faster access these pretty self explanatory we will watch for this and and and the drug company that is developing this thank you so much.
Filter by section